Urogen Pharma (URGN) closed the last trading session at $12.70, gaining 4.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $39.36 indicates a 209.9% upside potential.The average comprises seven short-term price targets ranging from a low of $18 to a high of $64, with a standard deviation of $15.76. While the lowest estimate indicates an increase of 41.7% from the current price le ...